Aveo-Astellas kidney cancer drug is not recommended by FDA advisers

05/3/2013 | Yahoo

An FDA advisory panel voted 13-1 against recommending approval of Aveo Pharmaceuticals and Astellas Pharma's tivozanib as treatment for kidney cancer, citing inconsistent data from a clinical trial. The panel said another trial would be needed. Though disappointed with the decision, Aveo and Astellas said they would consult with the agency to address the advisers' concerns.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX